Vitamin D3 Supplementation for Heart Failure Patients

• Status: Completed
• Trial end date: 2015-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if treatment with vitamin D3 of 10,000 International Units (IU) daily in vitamin D deficient patients for 6 months will improve B type natriuretic peptide (BNP), a marker of heart function, compared to placebo. The investigators also aim to determine if vitamin D helps cardiopulmonary function as evaluated by cardiopulmonary exercise test (CPX), laboratory values, strength, and quality of life in patients with stable congestive heart failure (Class II or III).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Heidi Moretti, MS, RD
• Collaborator: Saint Patrick Hospital
• Treatments: Cholecalciferol; Ergocalciferols; Vitamin D; Vitamins

Criteria

Inclusion Criteria:

• NYHA Heart Failure Class II or II, stable

• Vitamin D deficiency (32 ng/ml or less)

• No recent medication changes for 3 months

• Females of childbearing age must use effective contraceptive if they are sexually active

Exclusion Criteria:

• Hypercalcemia

• Nephrolithiases

• Sarcoidosis

• Acute cardiac insufficiency

• Pregnancy

• Breastfeeding

• Any clinically unstable medical condition

• Supplements of greater than or equal to 1000 units of vitamin D per day